Managing autonomic dysfunction in Parkinson’s disease: a review of emerging drugs

References

• Pfeiffer RF. Non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2016 Jan;22(Suppl 1):S119–22.
   PubMed Web of Science ®Google Scholar
• Kim HS, Cheon SM, Seo JW, et al. Non motor symptoms more closely related to Parkinson’s disease: comparison with normal elderly. J Neurol Sci. 2013 Jan 15;324(1–2):70–73.
   PubMed Web of Science ®Google Scholar
• Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002 Aug 13;59(3):408–413.
   PubMed Web of Science ®Google Scholar
• Merola A, Romagnolo A, Comi C, et al. Prevalence and burden of dysautonomia in advanced Parkinson’s disease. Mov Disord. 2017;32:796–797.
   PubMed Web of Science ®Google Scholar
• Mendoza-Velásquez JJ, Flores-Vázquez JF, Barrón-Velázquez E, et al. Autonomic dysfunction in a-synucleinopathies. Front Neurol. 2019 Apr;12(10):363.
   Google Scholar
• Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, et al. The impact of nonmotor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399–406.
   PubMed Web of Science ®Google Scholar
• Coon EA, Cutsforth-Gregory JK, Benarroch EE. Neuropathology of autonomic dysfunction in synucleinopathies. Mov Disord. 2018 Mar;33(3):349–358.
   PubMed Web of Science ®Google Scholar
• Fasano A, Visanji NP, Liu LWC, et al. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625–639.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chang L, Xie J, et al. Arginine vasopressin injected into the dorsal motor nucleus of the vagus inhibits gastric motility in rats. Gastroenterol Res Pract. 2016;2016:4618672.
   PubMedGoogle Scholar
• Lebouvier T, Neunlist M, Des Varannes SB, et al. Colonic biopsies to assess the neuropathology of Parkinson’s disease and its relationship with symptoms. PLoS ONE. 2010;5(9):e12728. ArticleID.
   PubMed Web of Science ®Google Scholar
• Liu L. Chronic constipation: current treatment options. Can J Gastroenterol. 2011;25:22B–28B.
   PubMedGoogle Scholar
• Bharucha AE, Pemberton JH, Locke GR. American gastroenterological association technical review on constipation. Gastroenterology. 2013 Jan;144(1):218–238.
   PubMed Web of Science ®Google Scholar
• Arya NG, Weissbart SJ. Central control of micturition in women: brain-bladder pathways in continence and urgency urinary incontinence. Clin Anat. 2017 Apr;30(3):373–384.. Epub 2017 Mar 9.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Tateno F, Kishi M, et al. Pathophysiology of bladder dysfunction in Parkinson’s disease. Neurobiol Dis. 2012 Jun;46(3):565–571.
   PubMed Web of Science ®Google Scholar
• Weiss JP, Blaivas JG, Bliwise DL, et al. The evaluation and treatment of nocturia: a consensus statement. BJU Int. 2011;108(1):6–21.
   PubMed Web of Science ®Google Scholar
• Xue P, Wang T, Zong H, et al. Urodynamic analysis and treatment of male Parkinson’s disease patients with voiding dysfunction. Chin Med J. 2014;127(5):878–881.
   PubMed Web of Science ®Google Scholar
• Dalmose AL, Bjarkam CR, Sorensen JC, et al. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourol Urodyn. 2004;23(3):265–272.
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Nakazawa K, Uchiyama T, et al. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience. 2003;120(3):871–875.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Sakakibara R, Hashimoto K, et al. Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience. 2005;135(1):299–303.
   PubMed Web of Science ®Google Scholar
• Shibao CA M.D.1, Kaufmann H. Pharmacotherapy of cardiovascular autonomic dysfunction in Parkinson disease. CNS Drugs. 2017 Nov;31(11):975–989.
   PubMed Web of Science ®Google Scholar
• Velseboer DC, de Haan RJ, Wieling W, et al. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2011 Dec;17(10):724–729.
   PubMed Web of Science ®Google Scholar
• Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord. 2015 Apr 15;30(5):639–645.
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Jordan J, Biaggioni I. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS). Endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res. 2018;28(4):355–362.
   PubMed Web of Science ®Google Scholar
• Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264:1567–1582.
   PubMed Web of Science ®Google Scholar
• Fanciulli A, Göbel G, Ndayisaba JP, et al. Supine hypertension in Parkinson’s disease and multiple system atrophy. Clin Auton Res. 2016 Apr;26(2):97–105.
   PubMed Web of Science ®Google Scholar
• Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018 Mar;33(3):372–390.
   PubMed Web of Science ®Google Scholar
• Kalf JG, de Swart BJ, Bloem BR, et al. Prevalence of oropharyngeal dysphagia in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord. 2012 May;18(4):311–315.
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Parkinsonism Relat Disord. 2011 Jan;17(1):10–15. AstarloaR, Mena MA, Sánchez V et al. Clinical and fiber on Parkinson disease. Clin Neuropharmacol. 1992 Oct;15(5):375–80.
   PubMed Web of Science ®Google Scholar
• Astarloa R, Mena MA, Sánchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol. 1992 Oct;15(5):375–380.
   PubMed Web of Science ®Google Scholar
• Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord. 1997 Nov;12(6):946–951.
   PubMed Web of Science ®Google Scholar
• Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of constipation in Parkinson’s disease patients. Minerva Gastroenterol Dietol. 2011 Jun;57(2):117–121.
   PubMedGoogle Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord. 2007 Jul 15;22(9):1239–1244.
   PubMed Web of Science ®Google Scholar
• Eichhorn TE, Oertel WH. Macrogol 3350/electrolyte improves constipation in Parkinson’s disease and multiple system atrophy. Mov Disord. 2001 Nov;16(6):1176–1177.
   PubMed Web of Science ®Google Scholar
• Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson’s disease. Mov Disord. 1997 May;12(3):423–425.
   PubMed Web of Science ®Google Scholar
• Camilleri M, Deiteren A. Prucalopride for constipation. Expert Opin Pharmacother. 2010;11:451–461.
   PubMed Web of Science ®Google Scholar
• Navailles S, Di Giovanni G, De Deurwaerdère P. The 5-HT4 agonist prucalopride stimulates L-DOPA-induced dopamine release in restricted brain regions of the hemiparkinsonian rat in vivo. CNS Neurosci Ther. 2015;21(9):745–747.
   PubMed Web of Science ®Google Scholar
• Pinyopornpanish K, Soontornpun A, Kijdamrongthum P, et al. The effect of prucalopride on gastric emptying in Parkinson’s disease patients, a pilot randomized, open-label study. Dig Sys. 2017;1(1):1–6.
   Google Scholar
• Freitas ME, Alqaraawi A, Lang AE, et al. Linaclotide and prucalopride for management of constipation in patients with parkinsonism. Mov Disord Clin Pract. 2018;5(2):218–220.
   PubMed Web of Science ®Google Scholar
• Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–177.
   PubMed Web of Science ®Google Scholar
• Barish CF, Drossman D, Johanson JF, et al. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55:1090–1097.
   PubMed Web of Science ®Google Scholar
• Thayalasekeran S, Ali H, Tsai HH. Novel therapies for constipation. World J Gastroenterol. 2013;19(45):8247–8251.
   PubMed Web of Science ®Google Scholar
• Ondo WG, Kenney C, Sullivan K, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012 May 22;78(21):1650–1654.
   PubMed Web of Science ®Google Scholar
• Bassotti G, Usai-Satta P, Bellini M. Linaclotide for the treatment of chronic constipation. Expert Opin Pharmacother. 2018 Aug;19(11):1261–1266.
   PubMed Web of Science ®Google Scholar
• Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010 May 8;86(19–20):760–765.
   PubMed Web of Science ®Google Scholar
• Ahsan MK, Tchernychev B, Kessler MM, et al. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine. Physiol Rep. 2017 Jun;5(11):e13299.
   PubMed Web of Science ®Google Scholar
• Chiu CM, Wang CP, Sung WH, et al. Functional magnetic stimulation in constipation associated with Parkinson’s disease. J Rehabil Med. 2009 Nov;41(13):1085–1089.
   PubMed Web of Science ®Google Scholar
• Krogh K, Chiarioni G, Whitehead W. Management of chronic constipation in adults. United European Gastroenterol J. 2017;5(4):465–472.
   PubMed Web of Science ®Google Scholar
• Albanese A, Brisinda G, Bentivoglio AR, et al. Treatment of outlet obstruction constipation in Parkinson’s disease with botulinum neurotoxin A. Am J Gastroenterol. 2003 Jun;98(6):1439–1440.
   PubMed Web of Science ®Google Scholar
• Cadeddu F, Bentivoglio AR, Brandara F, et al. Outlet type constipation in Parkinson’s disease: results of botulinum toxin treatment. Ailment Pharmacol Ther. 2005 Nov 15;22(10):997–1003.
   PubMed Web of Science ®Google Scholar
• Edwards LL, Quigley EM, Harned RK, et al. Defecatory function in Parkinson’s disease: response to apomorphine. Ann Neurol. 1993;33:490–493.
   PubMed Web of Science ®Google Scholar
• Griffiths DJ, McCracken PN, Harrison GM, et al. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn. 1993;12(1):1–7.
   PubMed Web of Science ®Google Scholar
• Batla A, Phé V, De Min L, et al. Nocturia in Parkinson’s disease: why does it occur and how to manage? Mov Disord Clin Pract. 2016 Jun 7;3(5):443–451.
   PubMed Web of Science ®Google Scholar
• Panicker JN, Fowler CJ, Kessler TM. Lower urinary tract dysfunction in the neurological patient: clinical assessment and management. Lancet Neurol. 2015 Jul;14(7):720–732.
   PubMed Web of Science ®Google Scholar
• Yamada S, Ito Y, Nishijima S. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder. Pharmacol Ther. 2018 Sep;189:130–148.
   PubMed Web of Science ®Google Scholar
• Batla A, Tayim N, Pakzad M, et al. Treatment options for urogenital dysfunction in Parkinson’s disease. Curr Treat Options Neurol. 2016 Oct;18(10):45.
   PubMed Web of Science ®Google Scholar
• Hajebrahimi S, Chapple CR, Pashazadeh F, et al. Management of neurogenic bladder in patients with Parkinson’s disease: a systematic review. Neurourology and Urodynamics. 2019;38:31–62.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Rossi A, Mearini E, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182:1453–1457.
   PubMed Web of Science ®Google Scholar
• Vurture G, Peyronnet B, Feigin A. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson’s disease. Neurourol Urodyn. 2018 Nov;37(8):2669–2677.
   PubMed Web of Science ®Google Scholar
• Gaziev G, Topazio L, Iacovelli V. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013 Nov;25(13):61.
   Google Scholar
• Kabay S, Kabay CS, Cetiner M. The clinical and urodynamic results of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Urology. 2016 Jan;87:76–81.
   PubMed Web of Science ®Google Scholar
• Schneier MP, Gross T, Bachmann LM, et al. Tibial nerve stimulation for treating neurogenic lower urinary tract dysfunction: a systematic review. Eur Urol. 2015 Nov;68(5):859–867.
   PubMed Web of Science ®Google Scholar
• Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord. 2018 Dec;57:22–26.
   PubMed Web of Science ®Google Scholar
• Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016 Oct;7(5):204–216.
   PubMed Web of Science ®Google Scholar
• Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014 Apr 3;10:169–176.
   PubMedGoogle Scholar
• Hauser RA, Biaggioni LI, Hewitt A, et al. Integrated analysis of droxidopa for the treatment of neurogenic orthostatic hypotension in patients with Parkinson disease. Mov Disord Clin Pract. 2018 Nov 8;5(6):627–634.
   PubMedGoogle Scholar
• Schreglmann SR, Büchele F, Sommerauer M, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson’s disease - a randomized controlled trial. Eur J Neurol. 2017 Apr;24(4):545–551.
   PubMed Web of Science ®Google Scholar
• Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging. 2001;18(7):495–505.
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Pavy-Le Traon A, et al. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs. 2013 Mar;18(1):39–53.
   PubMed Web of Science ®Google Scholar
• Palma JA, Norcliffe-Kaufmann L, Martinez J, et al. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology. 2018 Oct 16;91(16):e1539–e1544.
   PubMed Web of Science ®Google Scholar
• Jordan J, Biaggioni I. Diagnosis and treatment of supine hypertension in autonomic failure patients with orthostatic hypotension. J Clin Hypertens. 2002;4(2):139–145.
   Google Scholar
• Mobley DF, Khera M, Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017;93:679–685.
   PubMed Web of Science ®Google Scholar
• Randrup E, Baum N, Feibus A. Erectile dysfunction and cardiovascular disease. Postgrad Med. 2015;127:166–172.
   PubMed Web of Science ®Google Scholar
• Gul M, Serefoglu EC. An update on the drug safety of treating erectile dysfunction. Expert Opin Drug Saf. 2019 Oct;18(10):965–975.
   PubMed Web of Science ®Google Scholar
• Cai T, Palumbo F, Liguori G, et al. The intra-meatal application of alprostadil cream (Vitaros®) improves drug efficacy and patient’s satisfaction: results from a randomized, two-administration route, cross-over clinical trial. Int J Impot Res. 2019 Mar;31(2):119–125.
   PubMed Web of Science ®Google Scholar
• Allahdadi KJ, Tostes RC, Webb RC. Female sexual dysfunction: therapeutic options and experimental challenges. Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):260–269. AshrafW, Pfeiffer RF, Park F et al. Constipation in Parkinson’s disease: objective assessment and response to psyllium. Mov Disord. 1997 Nov;12(6):946–51.
   PubMedGoogle Scholar
• Hyson HC, Johnson AM, Jog MS. Sublingual atropine for sialorrhea secondary to parkinsonism: a pilot study. Mov Disord. 2002 Nov;17(6):1318–1320.
   PubMed Web of Science ®Google Scholar
• Arbouw MEL, Movig KLL, Koopmann M. Glycopyrrolate for sialorrhea in Parkinson disease - a randomized, double-blind, crossover trial. Neurology. 2010;74:1203–1207.
   PubMed Web of Science ®Google Scholar
• Srivanitchapoom P, Pandey S, Hallett M. Drooling in Parkinson’s disease: a review. Parkinsonism Relat Disord. 2014 Nov;20(11):1109–1118.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Blázquez C, Forjaz MJ, Lizán L. Estimating the direct and indirect costs associated with Parkinson’s disease. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):889–911.
   PubMed Web of Science ®Google Scholar
• Reese JP, Dams J, Winter Y. Pharmacoeconomic considerations of treating patients with advanced Parkinson’s disease. Expert Opin Pharmacother. 2012 May;13(7):939–958.
   PubMed Web of Science ®Google Scholar
• Arnold AC, Jessica NG, Lei L, et al. Autonomic dysfunction in cardiology – pathophysiology, investigation, and management. Can J Cardiol. 2017 Dec;33(12):1524–1534.
   PubMed Web of Science ®Google Scholar
• Brundin P, Dave KD, Kordowera JH. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 Dec;298(Pt B):225–235.
   PubMedGoogle Scholar
• Miller AJ, Arnold AC. The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications. Clin Auton Res. 2019 Apr;29(2):231–243.
   PubMed Web of Science ®Google Scholar
• Poirier A, Aubé B, Côté M, et al. Gastrointestinal dysfunctions in Parkinson’s disease: symptoms and treatments. Parkinsons Dis. 2016;2016:6762528.
   PubMedGoogle Scholar
• Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson’s disease. Lancet Neurol. 2008;7(10):927–938.
   PubMed Web of Science ®Google Scholar
• Smith JA, Beattie DT, Marquess D, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:125–137.
   PubMed Web of Science ®Google Scholar
• Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:139–147.
   PubMed Web of Science ®Google Scholar
• Dennis D, Palme M, Irwin I, et al. ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dogs. Gastroenterol. 2004;126:641.
   PubMed Web of Science ®Google Scholar
• Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012;35:745–767.
   PubMed Web of Science ®Google Scholar
• Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014 Feb;39(3):239–253.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [Cited 2000 Feb 29] - . Identifier: NCT02838797, RQ-00000010 for Gastroparesis and Constipation in Parkinson’s Disease (RQ-10); 2016 July [Verified Dec 2018]; [about 4 screens]. [cited 2019 Oct]. Available from: http://clinicaltrials.gov/ct/show/NCT02838797
   Google Scholar
• Parkinson Study Group. A randomized trial of relamorelin for constipation in Parkinson’s disease (MOVE-PD): trial results and lessons learned. Parkinsonism Relat Disord. 2017 Apr;37:101–105.
   PubMed Web of Science ®Google Scholar
• Mosinska P, Zatorski H, Storr M, et al. Future treatment of constipation-associated disorders: role of relamorelin and other ghrelin receptor agonists. J Neurogastroenterol Motil. 2017;23(2):171–179.
   PubMed Web of Science ®Google Scholar
• Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2018;11:1756284818777945.
   Web of Science ®Google Scholar
• Perni MC, Galvagnion A, Maltsev G, et al. A natural product inhibits the initiation of alpha-synuclein aggregation and suppresses its toxicity. Proc Natl Acad Sci U S A. 2017;114(6):pp. E1009-E1017.
   Web of Science ®Google Scholar
• Hauser RA, Sutherland D, Madrid JA, et al. Targeting neurons in the gastrointestinal tract to treat Parkinson’s disease. Clinical Parkinsonism & Related Disorders. 2019;1:2–7.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine(US). [Cited 2000 Feb 29 - . Identifier: NCT03781791, Orally Administered ENT-01 for Parkinson’s Disease-Related Constipation (KARMET); 2018 Dec [Verified Jul 2019]; [about 4 screens]. [cited 2019 Dec]. Available from: http://clinicaltrials.gov/ct/show/NCT03781791
   Google Scholar
• Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013;22:277–284.
   PubMed Web of Science ®Google Scholar
• Mitcheson HD, Samanta S, Muldowney K. Vibegron (RVT-901/MK-4618/KRP-114V) administered once daily as monotherapy or concomitantly with tolterodine in patients with an overactive bladder: a multicenter, phase IIb, randomized, double-blind, controlled trial. Eur Urol. 2019 Feb;75(2):274–282.
   PubMed Web of Science ®Google Scholar
• Keam SJ. Vibegron: first global approval. Drugs. 2018 Nov;78(17):1835–1839.
   PubMed Web of Science ®Google Scholar
• Pinyopornpanish K, Soontornpun A, Kijdamrongthum P, et al. The effect of prucalopride on gastric emptying in Parkinson’s disease patients, a pilot randomized, open-label study. Dig Sys. 2017;1(1):1–6.
   Google Scholar